Literature DB >> 825033

Nosocomial infection with gentamicin-carbenicillin-resistant Pseudomonas aeruginosa.

I M Baird, J M Slepack, C A Kauffman, J P Phair.   

Abstract

Pseudomonas aeruginosa resistant to both gentamicin and carbenicillin was isolated with increasing frequency at the Cincinnati Veterans Administration Hospital during the period 1971 to 1974. A comparison of patients from whom P. aeruginosa was isolated during this period failed to reveal any significant clinical differences between the patients colonized or infected with resistant organisms and those colonized or infected with susceptible organisms. Overt clinical infection attributable to either organism was rare. The antibiotic-resistant organisms were isolated most frequently from urine. Isolation of the antibiotic-resistant organisms was more frequent from patients who had previously received gentamicin.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 825033      PMCID: PMC429805          DOI: 10.1128/AAC.10.4.626

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Pseudomonas in the hospital.

Authors:  J J Farmer
Journal:  Hosp Pract       Date:  1976-02

Review 2.  Management of infections in patients with leukemia and lymphoma: current concepts and experimental approaches.

Authors:  A S Levine; R G Graw; R C Young
Journal:  Semin Hematol       Date:  1972-04       Impact factor: 3.851

3.  Transfer of gentamicin resistance from Pseudomonas aeruginosa strains highly resistant to gentamicin and carbenicillin.

Authors:  H Knothe; V Krcméry; W Sietzen; J Borst
Journal:  Chemotherapy       Date:  1973       Impact factor: 2.544

Review 4.  Hospital-acquired infections.

Authors:  D S Feingold
Journal:  N Engl J Med       Date:  1970-12-17       Impact factor: 91.245

5.  Nosocomial infections.

Authors:  R F Fekety
Journal:  Postgrad Med       Date:  1971-11       Impact factor: 3.840

6.  Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center.

Authors:  W H Greene; M Moody; S Schimpff; V M Young; P H Wiernik
Journal:  Ann Intern Med       Date:  1973-11       Impact factor: 25.391

7.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

8.  An improved single-disk method for testing the antibiotic susceptibility of rapidly-growing pathogens.

Authors:  A L Barry; F Garcia; L D Thrupp
Journal:  Am J Clin Pathol       Date:  1970-02       Impact factor: 2.493

9.  Gentamicin-resistant Pseudomonas aeruginosa and Serratia marcescens in a general hospital.

Authors:  R D Meyer; R P Lewis; J Halter; M White
Journal:  Lancet       Date:  1976-03-13       Impact factor: 79.321

10.  Resistance of Pseudomonas aeruginosa to gentamicin.

Authors:  P Chadwick
Journal:  Can Med Assoc J       Date:  1973-10-06       Impact factor: 8.262

View more
  4 in total

1.  Antibacterial activity of apalcillin (PC-904) against gram-negative bacilli, especially ampicillin-, carbenicillin-, and gentamicin-resistant clinical isolates.

Authors:  H Noguchi; M Kubo; S Kurashige; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

2.  Surveillance of gentamicin-resistant gram-negative bacilli in a general hospital.

Authors:  C A Kauffman; N C Ramundo; S G Williams; C R Dey; J P Phair; C Watanakunakorn
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

3.  In vitro susceptibility of gentamicin and/or tobramycin resistant gram-negative bacilli to seven aminoglycosides.

Authors:  C Watanakunakorn; C A Kauffman
Journal:  Infection       Date:  1978       Impact factor: 3.553

4.  Gentamicin use and Pseudomonas and Serratia resistance: effect of a surgical prophylaxis regimen.

Authors:  N J Roberts; R G Douglas
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.